buyModerate cluster of 2
Opaleye Management Inc. bought $241k of TCON
owner at Tracon Pharmaceuticals, Inc.. 174,508 shares at an average of $1.38, traded Mar 9, 2023, filed Mar 13, 2023.
Conviction score
43Value
$241k
174,508 shares
Holdings after
4,324,508
+4% from before
From 52-week low
-
no price yet
From 52-week high
-
no price yet
Score components
- +12Role10% owner
- +13Trade size$241k at market
- 0Relative to holdingsHoldings up 4.2%
- 0Price contextNo price history yet
- +8Cluster2 insiders buying within 14 days
- +5Repeat buying2 buys in 90 days
- +10Track recordMedian 6-month excess return +31% over 61 past buys
- -5Outside holderA 10% owner who is not an officer or director
What happened after comparable buys
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Rows in this filing
Every transaction in Form 4 0001493152-23-007400, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Mar 9, 2023 | POpen-market purchase Common Stock, par value $0.001 per shareindirect: By Opaleye, L.P. | +174,508 | $1.38 | $241k | 4,324,508 | Mar 13, 2023 |
Related signals
Other insiders at Tracon Pharmaceuticals, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 57Moderate | TCONsell Tracon Pharmaceuticals, Inc. | Opaleye Management Inc. owner | $1.4M 4,764,008 shares | -110% | |
| 39Weak | TCONbuy Tracon Pharmaceuticals, Inc. | Charles Theuer President and CEO | $38k 50,999 shares | +15% | |
| 38Weak | Tracon Pharmaceuticals, Inc. | Charles Theuer President and CEO | $7,600 5,000 shares | +1% | |
| 15Weak | TCONsell Tracon Pharmaceuticals, Inc. | William R Larue director | $151 120 shares | -2% | |
| 30Weak | TCONbuy Tracon Pharmaceuticals, Inc. | Charles Theuer President and CEO | $11k 6,800 shares | +2% | |
| 25Weak | TCONbuy Tracon Pharmaceuticals, Inc. | Scott B. Brown Chief Financial Officer | $5,215 3,500 shares | +19% | |
| 42Moderate | Tracon Pharmaceuticals, Inc. | Opaleye Management Inc. owner | $210k 167,500 shares | +4% | |
| 46Moderate | Tracon Pharmaceuticals, Inc. | Charles Theuer President and CEO | $30k 23,000 shares | +7% | |
| 12Weak | TCONsell Tracon Pharmaceuticals, Inc. | Opaleye Management Inc. owner | $2,216 1,539 shares | -0% | |
| 30Weak | TCONbuy Tracon Pharmaceuticals, Inc. | Charles Theuer President and CEO | $20k 13,900 shares | +5% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.